Form 4 for KTTA Pasithea Therapeutics Corp.

Accepted 2021-12-22 00:00:00 ET · period of report 2021-12-20 · accession 0001213900-21-067062 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-12-22	2021-12-20	KTTA	Marques Tiago	CEO, Dir	A - Grant	$0.00	+200.0K	800.0K	+33%	$0
D	2021-12-22	2021-12-20	KTTA	Marques Tiago	CEO, Dir	A - Grant	$0.00	+200.0K	200.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-12-20	A	A	200,000	$0.00	800,000	D	—	—	(F1) The Reporting Person was granted Restricted Stock Units which shall vest into common stock of the Company over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter.
2	Derivative	Stock Option (to acquire Common Stock)	2021-12-20	A	A	200,000	$0.00	200,000	D	$1.44 · 2022-12-20 to 2031-12-20	200,000 Common Stock	(F2) The Reporting Person was granted 200,000 stock options. The stock options have a ten-year term and vest over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter.